Expertise in
16
conditions

Dr. Chi K. Tsang

Radiation Oncology
Nyc Health Hospitals / Elmhurst
7901 Broadway, 
Elmhurst, NY 
Expertise in
16
conditions
Nyc Health Hospitals / Elmhurst
7901 Broadway, 
Elmhurst, NY 

Overview

Chi Tsang is a Radiation Oncologist practicing medicine in Elmhurst, New York.

Dr. Tsang is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Small Cell Lung Cancer (SCLC), Angiosarcoma, Pleuropulmonary Blastoma, and Lung Cancer.

He is actively involved in clinical research, co-authoring 34 peer reviewed articles and participating in 7 clinical trials.

Specialties

Radiation Oncology

Licenses

Radiology in NY

Hospital Affiliations

Penn State Health Hampden Medical Center
Elmhurst Hospital Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID

Locations

Nyc Health Hospitals / Elmhurst
7901 Broadway, Elmhurst, NY 11373
Other Locations
Arnot Health
600 Roe Ave, Elmira, NY 14905

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2026
Intervention Type: Other, Procedure
Study Phase: Phase 3
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Enrollment Status: Suspended
Publish Date: September 01, 2026
Intervention Type: Procedure, Drug, Other, Radiation, Biological
Study Drugs: Atezolizumab, Cetuximab, Cisplatin, Docetaxel
Study Phase: Phase 2/Phase 3
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
Enrollment Status: Active_not_recruiting
Publish Date: August 17, 2026
Intervention Type: Drug, Radiation
Study Drugs: Bicalutamide, Buserelin, Darolutamide, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Relugolix, Triptorelin
Study Phase: Phase 3
Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer
Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: July 10, 2026
Intervention Type: Radiation
Study Phase: Phase 2/Phase 3
A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)
A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)
Enrollment Status: Completed
Publish Date: July 09, 2026
Intervention Type: Other, Radiation
Study Phase: Phase 3
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Enrollment Status: Active_not_recruiting
Publish Date: May 08, 2026
Intervention Type: Radiation, Drug
Study Phase: Phase 3
RT CHARM: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation With Breast Reconstruction
RT CHARM: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation With Breast Reconstruction
Enrollment Status: Active_not_recruiting
Publish Date: February 24, 2026
Intervention Type: Other, Radiation
Study Phase: Phase 3
View 6 Less Clinical Trials

34 Total Publications

SOD1 regulates CXCR4 transcription in cortical neurons for establishment of cerebral ischemic tolerance.
SOD1 regulates CXCR4 transcription in cortical neurons for establishment of cerebral ischemic tolerance.
Journal: Journal of advanced research
Published: May 10, 2025
Similar Doctors
Expertise in
17
conditions
Dr. Andreas Rimner
Radiation Oncology
Expertise in
17
conditions
Dr. Andreas Rimner
Radiation Oncology
Referral may be required

Memorial Sloan Kettering Cancer Center

1275 York Ave, 
New York, NY 
 (3.9 miles away)
212-639-2000
Languages Spoken:
English

Andreas Rimner is a Radiation Oncologist practicing medicine in New York, New York. Dr. Rimner is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Tissue Biopsy, and Thymectomy.

Expertise in
54
conditions
Dr. Kaled M. Alektiar
Radiation Oncology
Expertise in
54
conditions
Dr. Kaled M. Alektiar
Radiation Oncology
Referral may be required

Memorial Sloan Kettering Cancer Center

1275 York Ave, 
New York, NY 
 (3.9 miles away)
646-582-9491
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kaled Alektiar is a Radiation Oncologist practicing medicine in New York, New York. Dr. Alektiar is highly rated in 54 conditions, according to our data. His clinical expertise encompasses Endometrial Cancer, Adult Soft Tissue Sarcoma, Fibrosarcoma, Cervical Cancer, and Lymphadenectomy. Dr. Alektiar is currently accepting new patients.

Expertise in
17
conditions
Dr. Joachim Yahalom
Radiation Oncology
Expertise in
17
conditions
Dr. Joachim Yahalom
Radiation Oncology
Referral may be required

Memorial Sloan Kettering Cancer Center

1275 York Ave, 
New York, NY 
 (3.9 miles away)
929-459-8263
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Joachim Yahalom is a Radiation Oncologist practicing medicine in New York, New York. Dr. Yahalom is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Hodgkin Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma (MZL), Plasmacytoma, and Tissue Biopsy. Dr. Yahalom is currently accepting new patients.

Frequently Asked Questions about Dr. Chi K. Tsang

How do I make an appointment with Dr. Chi K. Tsang?

You can book an appointment with Dr. Chi K. Tsang by calling their office at 718-334-4000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Chi K. Tsang a top-rated expert for Small Cell Lung Cancer (SCLC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Chi K. Tsang is classified as an Distinguished expert for Small Cell Lung Cancer (SCLC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Chi K. Tsang specialize in?

While Dr. Chi K. Tsang is a Radiation Oncology, they have specific expertise in Small Cell Lung Cancer (SCLC), Angiosarcoma, and Pleuropulmonary Blastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Chi K. Tsang participate in research or clinical trials?

Yes. Dr. Chi K. Tsang has published 34 articles and abstracts on conditions like Small Cell Lung Cancer (SCLC). You can view a list of Dr. Chi K. Tsang's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Chi K. Tsang accept my insurance?

Dr. Chi K. Tsang accepts most major insurance plans, including Blue Cross Blue Shield and Cigna. We recommend calling the office directly at 718-334-4000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tsang's expertise for a condition
ConditionClose
    View All 14 Advanced Conditions
    View All 30 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile